What Researchers Did
This review explored the pathophysiology of filler-induced vascular occlusion (FIVO) and the multifaceted role of hyperbaric oxygen therapy (HBOT) in managing this complication.
What They Found
Researchers found that hyperbaric oxygen therapy (HBOT) acts as an adjunctive treatment for filler-induced vascular occlusion (FIVO) through its vasodilatory, anti-spasmodic, and anti-inflammatory effects. Optimal efficacy requires timely intervention, adherence to specific pressures of two atmosphere absolute, and session durations of 60 minutes.
What This Means for Canadian Patients
For Canadian patients experiencing filler-induced vascular occlusion, hyperbaric oxygen therapy (HBOT) may offer an adjunctive treatment option to help salvage ischaemic tissue. However, it is crucial for patients to seek immediate medical attention for any suspected vascular complications after aesthetic filler procedures.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
Standardised guidelines for hyperbaric oxygen therapy in filler-induced vascular occlusion are lacking, and further research is needed to define its definitive role.